SK286019B6 - Nasal ointment for the prevention of inhalation allergic reactions - Google Patents
Nasal ointment for the prevention of inhalation allergic reactions Download PDFInfo
- Publication number
- SK286019B6 SK286019B6 SK1281-2000A SK12812000A SK286019B6 SK 286019 B6 SK286019 B6 SK 286019B6 SK 12812000 A SK12812000 A SK 12812000A SK 286019 B6 SK286019 B6 SK 286019B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ointment
- saturated hydrocarbon
- nasal
- nasal ointment
- hydrocarbon mixture
- Prior art date
Links
- 229940100657 nasal ointment Drugs 0.000 title claims abstract description 22
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000002674 ointment Substances 0.000 claims abstract description 18
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 13
- 235000019271 petrolatum Nutrition 0.000 claims description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 239000004264 Petrolatum Substances 0.000 claims description 5
- 229940066842 petrolatum Drugs 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 235000004866 D-panthenol Nutrition 0.000 claims description 4
- 239000011703 D-panthenol Substances 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- -1 pantenyl ethyl ether Chemical compound 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 229960003949 dexpanthenol Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229960003504 silicones Drugs 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 235000005881 Calendula officinalis Nutrition 0.000 claims 1
- 240000000950 Hippophae rhamnoides Species 0.000 claims 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims 1
- 240000000785 Tagetes erecta Species 0.000 claims 1
- 238000004817 gas chromatography Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 13
- 239000013566 allergen Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 1
- KACYSVCDWJOGJC-UHFFFAOYSA-N C(C)(=O)O.C(C)OCCCCC Chemical compound C(C)(=O)O.C(C)OCCCCC KACYSVCDWJOGJC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Predkladaný vynález sa týka nosovej masti obsahujúcej zmesi, ktoré majú pri izbovej teplote gélovitý charakter a prevládajú v nich nasýtené uhľovodíky, a ďalej využitia tejto masti k ochrane oproti inhalačným alergickým reakciám, predovšetkým atopickej (chronickej) nádche, ktorá sa prejavuje ako „senná nádcha“. Predovšetkým je dôležité zdôrazniť, že masť opisovaná v predkladanom vynáleze obsahuje tiež aspoň jednu ošetrujúcu prísadu pre masti.The present invention relates to a nasal ointment containing compositions having a gel-like character at room temperature and saturated hydrocarbons predominant therein, and to the use of the ointment to protect against inhalation allergic reactions, in particular atopic (chronic) rhinitis, which is manifested as "hay fever" . In particular, it is important to emphasize that the ointment described in the present invention also comprises at least one treatment additive for ointments.
V západných priemyselných civilizáciách sú dnes inhalačné alergie veľmi rozšírené a stále ich pribúda. Prejavujú sa predovšetkým ako atopická nádcha vyvolaná peľom, výtrusmi húb, rôznymi typmi prachových častíc (napríklad drevený prach, kvetinový peľ alebo domáci prach) a tiež chemickými, prípadne biologickými dráždidlami (perie, vlasy), ktoré môžu, ak sa vyskytujú vo forme kontaminantov, silne zhoršiť zdravotný stav pacienta a dokonca spôsobiť jeho pracovnú neschopnosť.In Western industrial civilizations, inhalation allergies are now widespread and increasing. They are mainly manifested as atopic rhinitis caused by pollen, fungal spores, various types of dust particles (eg wood dust, flower pollen or household dust) and also chemical or biological irritants (feathers, hair), which may, if present in the form of contaminants, severely deteriorate the patient's health and even cause the patient's incapacity for work.
Príznaky, ako je nepríjemné svrbenie v nose, hltane, pripadne zadnej časti krku a pálenie očí, po ktorých nasleduje slzenie, kýchanie a silná nádcha, sú často sprevádzané bolesťami hlavy, podráždenosťou, nechutenstvom, depresiami a nespavosťou. Nasledovne sa môžu prejaviť aj závažnejšie príznaky - kašeľ a ťažké astmatické dýchanie.Symptoms such as unpleasant itching in the nose, the pharynx, or the back of the neck, and burning eyes, followed by tearing, sneezing and severe rhinitis, are often accompanied by headache, irritability, anorexia, depression and insomnia. The following may also be more severe symptoms - cough and severe asthmatic breathing.
Základnou formou alergickej nádchy je tak prezývaná „senná nádcha“, ktorá má sezónny charakter a prejavuje sa reakciami na pele stromov, kríkov, rôznych druhov tráv a lúčnych alebo okrasných kvetín.The basic form of allergic rhinitis is the so-called “hay rhinitis”, which is of a seasonal nature and is manifested by reactions to the pollen of trees, shrubs, different types of grasses and meadow or ornamental flowers.
Na utlmenie prípadne celkovú elimináciu príznakov inhalačných alergických reakcií slúži celý rad terapeutických a profylaktických krokov, ktoré sa viac či menej významne líšia cenou, efektívnosťou, vedľajšími účinkami na zdravie pacienta a vhodnosťou použitia.A variety of therapeutic and prophylactic steps, which vary more or less significantly in price, efficiency, side effects on patient health, and suitability for use, are used to attenuate or generally eliminate symptoms of inhaled allergic reactions.
A tak liečbu, ktorá vyžaduje vo vrcholnej peľovej sezóne presun pacienta na niekoľko týždňov zo zaťaženej oblasti do lokality s nízkou koncentráciou peľu, napríklad do horských oblasti s vyššou nadmorskou výškou alebo na ostrovy s malým vegetačným pokryvom, alebo vyžaduje dokonca zmenu bydliska prípadne zamestnania, aby sa pacient vyhol nežiaducim vplyvom, si môže ťažko dožičiť väčší počet chorých.Thus, in the peak pollen season, a treatment that requires moving the patient for a few weeks from a contaminated area to a low pollen concentration site, such as a high altitude area or islands with low vegetation cover, or even a change of residence or occupation, If the patient has avoided adverse effects, it can be difficult to survive a greater number of patients.
Ochrana proti nežiaducim účinkom tiež zahrnuje snahu o odstránenie alergénov vyvolávajúcich poruchy z pacientovho dosahu tak ďaleko, ako je to iba možné.Protection against adverse effects also includes the effort to remove as far as possible the allergens causing the disorders from the patient's reach.
Celkové odstránenie inhalačných alergénov však nie je možné. Je tu iba určitá šanca odstrániť kontaktný povrch vhodný pre alergén, v tomto prípade sliznicu, na ktorej dochádza k reakcii. Tento postup sa opisuje ako čiastočné odstránenie účinkov ohrozenia.However, total elimination of inhaled allergens is not possible. There is only a chance to remove the contact surface suitable for the allergen, in this case the mucous membrane on which the reaction occurs. This procedure is described as a partial elimination of the effects of the threat.
Antialergénne filtre inštalované do ventilácií a klimatizácií v bytoch, na pracoviskách a v autách môžu zamedziť nežiaducim účinkom iba v takto špeciálne chránených priestoroch a ich cena zvyčajne nie je zanedbateľná.Antiallergenic filters installed in ventilation and air-conditioning systems in apartments, workplaces and cars can only prevent adverse effects in specially protected areas and their cost is usually not negligible.
Respirátor umiestený cez nos a ústa je síce cenovo dostupný a účinný, ale je nepohodlný, a teda nevhodný.A respirator placed over the nose and mouth is affordable and effective, but is uncomfortable and therefore inappropriate.
Obmedzenie citlivosti proti alergénu (hyposenzitizácia, imunizácia) vyžaduje dôkladné a náročné testy na výber účinnej protilátky. Nedá sa spoľahlivo predpovedať, či bude výsledkom liečby klinické zlepšenie stavu pacienta. Táto metóda navyše nie je bez rizika výskytu nebezpečných vedľajších príznakov, napríklad dýchavičných stavov a vyrážky. Okrem toho imunizačná liečba je relatívne časovo náročná a drahá.Limiting allergen sensitivity (hyposensitization, immunization) requires thorough and demanding tests to select an effective antibody. It cannot be reliably predicted whether treatment will result in a clinical improvement in the patient's condition. In addition, this method is not without the risk of occurrence of dangerous side effects, such as shortness of breath and rash. In addition, immunization treatment is relatively time consuming and expensive.
Symptomatická liečba alergie orálnymi antihistaminikami vedúcimi ku zníženiu otokov sliznice je v prípade mnohých preparátov spojovaná s rizikom sedatívnych účinkov, ktoré majú vplyv na pacientov celkový stav a rýchlosť jeho reakcií. Navyše sa pri tejto liečbe zvyčajne vyskytujú vedľajšie účinky, ako napríklad bolesti hlavy, sucho v ústach a zvýšené riziko psychických porúch.Symptomatic treatment of allergy with oral antihistamines leading to a reduction in mucosal edema is associated with the risk of sedative effects affecting the patient's general condition and reaction rate in many preparations. In addition, side effects such as headaches, dry mouth and an increased risk of psychiatric disorders usually occur with this treatment.
Okrem iných možností sa na liečbu používajú tiež sympatomimetiká - prípravky na báze chrómglycinovej kyseliny a glukokortikoidov, nie sú rovnako príliš vhodné vzhľadom na rad vedľajších účinkov a tiež vysokú cenu.Among other treatments, sympathomimetics - chromglycine acid and glucocorticoid preparations - are also used for treatment, they are not as well suited for a number of side effects as well as high cost.
Doterajší stav technikyBACKGROUND OF THE INVENTION
Detailný opis doterajšieho stavu techniky sa odkazuje na postup uvedený v patente DE-C 41 17 887. Ten vychádza z použitia nasýtených uhľovodíkov, ktoré sa z farmaceutického a kozmetického hľadiska definujú ako vazelína a ako nosová masť na ochranu oproti inhalačným alergickým reakciám, predovšetkým „sennej nádche“ pričom používaná vazelína má nasledujúce vlastnosti:A detailed description of the state of the art refers to the process disclosed in DE-C 41 17 887. This is based on the use of saturated hydrocarbons, which are defined in pharmaceutical and cosmetic terms as petrolatum and as a nasal ointment to protect against inhalation allergic reactions, in particular vaseline ', the grease used has the following characteristics:
- bod tuhnutia podľa DIN 51 556 metódy: 49° až 52 °C;pour point according to DIN 51 556 method: 49 ° to 52 ° C;
- viskozita podľa DIN 51 562 metódy: 6 mm2/s (100 °C);- viscosity according to DIN 51 562 method: 6 mm 2 / s (100 ° C);
- penetrácia podľa DIN 51 580 metódy: 150 až 170;penetration according to DIN 51 580 method: 150 to 170;
- zvyčajná dĺžka uhľovodíkového reťazca vo vazelíne:- usual length of hydrocarbon chain in petroleum jelly:
26+1 uhlíkový atóm; - číslo uhlíka v uhľovodíkovom reťazci: C]5 až Ceo·26 + 1 carbon atom; - carbon number in the hydrocarbon chain: C 15 to C eo ·
Na rozdiel od vazelíny opisovanej v patente DE-C 41 17 887, vazelína používaná v súlade s týmto vynálezom obsahuje väčší podiel nasýtených uhľovodíkov s dlhým uhlíkovým reťazcom.Unlike the petrolatum described in DE-C 41 17 887, the petrolatum used in accordance with the present invention contains a larger proportion of long-chain saturated hydrocarbons.
Oproti doterajšiemu stavu výrobok uskutočnený v súlade s predkladaným vynálezom prináša zlepšenie vlastností nosovej masti, predovšetkým v spoľahlivosti ich antialergénnych účinkov. Nová nosová masť má také vlastnosti, že pacient pri jej aplikácii nenesie žiadne zdravotné riziká, masť predstavuje širokospektrálny inhalačný antialergén, je príjemná na používanie a navyše, liečba je cenovo dostupná.In contrast to the prior art, an article made in accordance with the present invention provides an improvement in the properties of the nasal ointment, in particular in the reliability of their antiallergenic effects. The new nasal ointment has such properties that the patient bears no health risks when applied, the ointment is a broad-spectrum inhaled antiallergen, is pleasant to use and, moreover, the treatment is affordable.
Podstata vynálezuSUMMARY OF THE INVENTION
Predmetom vynálezu je nosová masť na profylaxiu inhalačných alergických reakcií pozostávajúca z aspoň jednej zmesi nasýtených uhľovodíkov, ktorej podstata spočíva v tom, že aspoň jedna zmes nasýtených uhľovodíkov má viskozitu podľa metódy DIN 51562 vyššiu ako 6 mm2/s pri 100 °C, pričom masť prípadne obsahuje aspoň jednu ošetrujúcu zložku.The invention relates to a nasal ointment for the prophylaxis of inhaled allergic reactions comprising at least one saturated hydrocarbon mixture, characterized in that at least one saturated hydrocarbon mixture has a viscosity according to DIN 51562 of greater than 6 mm 2 / s at 100 ° C, wherein the ointment optionally, it comprises at least one treatment component.
Na vazelínu použiteľnú na účely predkladaného vynálezu sa nekladú žiadne zvláštne obmedzenia, pokiaľ vyhovuje farmaceutickým a kozmetickým požiadavkám na čistotu a kvalitu v súlade s DAB ustanoveniami a má zvyčajné vlastnosti nevyhnutné na realizáciu predkladaného vynálezu.Vaseline useful for the purposes of the present invention is not particularly limited as long as it meets the pharmaceutical and cosmetic requirements of purity and quality in accordance with the DAB provisions and has the usual properties necessary to practice the present invention.
Vazelína použitá v súlade s predkladaným vynálezom má viskozitu pri 100 °C podľa DIN 51 562 metódy >6 mm2/s, najlepšie >8 mm2/s, zvyčajne v rozmedzí 8,5 až 15 mm2/s.The petroleum jelly used in accordance with the present invention has a viscosity at 100 ° C according to DIN 51 562 of the method> 6 mm 2 / s, preferably> 8 mm 2 / s, usually in the range 8.5 to 15 mm 2 / s.
Prednostne sa používa vazelína, ktorá má aspoň jednu z nasledujúcich vlastností a) až e):Preferably, petroleum jelly having at least one of the following characteristics a) to e) is used:
a) bod tuhnutia DIN 51556 je 47 až 56 °C;(a) the pour point of DIN 51556 is 47 to 56 ° C;
b) penetrácia podľa DIN 51580 metódy je 155 až 185;b) penetration according to DIN 51580 method is 155 to 185;
c) maximálne 5 % hmotnostných nasýtených uhľovodíkov má dĺžku reťazca <25+2;(c) a maximum of 5% by weight of saturated hydrocarbons has a chain length of <25 + 2;
d) uhlíkový reťazec v nasýtených uhľovodíkoch (GC stanovenie) obsahuje C19 až C52, v každom prípade +2;(d) the carbon chain in saturated hydrocarbons (GC determination) contains C19 to C52 , in each case +2;
e) hodnota priemernej molekulovej hmotnosti: >400, najlepšie >480, zvyčajne >500 g/mol.(e) average molecular weight:> 400, preferably> 480, usually> 500 g / mol.
Ako ošetrujúce prísady do masti sa používajú všetky známe prípravky vyrábané pre tieto účely, najmä silikóny, pantenol, lanolín, lecitín, dexpantenol, provitaminB5, pantotenová kyselina, pantenyletyl éter, pentyletyléter acetát, pantenyl triacetát, alantoín, rastlinný olej (prípadne olej z rias a lišajníkov), ako napríklad mandľový olej, olej z pšeničných klíčkov, avokádový olej, ďalej vosky, napríklad parafíny, a konečne extrakty (predovšetkým v oxide uhličitom), ako napríklad rumančekový rešetliakový alebo nechtikový extrakt.All known preparations for this purpose are used as ointment additives, in particular silicones, panthenol, lanolin, lecithin, dexpanthenol, provitamin B5, pantothenic acid, pantenylethyl ether, pentylethyl ether acetate, pantenyl triacetate, allantoin, vegetable oil (or algae oil) lichens), such as almond oil, wheat germ oil, avocado oil, waxes such as paraffins, and finally extracts (especially in carbon dioxide) such as chamomile creeper or lentil extract.
Nosová masť opisovaná v predkladanom vynáleze sa môže aplikovať prstom alebo pomocou aplikátora. Z hľadiska efektívnosti ochrany oproti alergickým reakciám je však celkom zásadné rozvrstvenie masti v nosovej dutine. Aby bol spoľahlivo dosiahnutý žiadaný účinok, musí sa masť rozotrieť po vnútornej strane obidvoch nosových dierok, po celej ploche nosovej sliznice.The nasal ointment described in the present invention may be applied by finger or by an applicator. However, stratification of the ointment in the nasal cavity is essential for the effectiveness of protection against allergic reactions. In order to reliably achieve the desired effect, the ointment must be spread on the inside of both nostrils, over the entire area of the nasal mucosa.
V prípade, že sa nosová masť zodpovedajúca predkladanému vynálezu aplikuje iba na spodný okraj nosových dierok a okolo nosa, nedá sa zabrániť inhalačnej alergickej reakcii. Ak sa však masť aplikuje správne, je možné sa pomocou tejto masti vyvarovať aspoň čiastočne účinkom inhalačných alergénov. Vzhľadom ku špecifickým fyzikálnym vlastnostiam nosová masť zodpovedajúca predkladanému vynálezu nemôže prenikať stenou nosovej sliznice, preto sa nevstrebáva a ostáva na povrchu ako ochranný film. Tak sa vytvorí mechanická bariéra oproti prenášačom alergénov zachyteným a transportovaným vdychovaným vzduchom. Týmto spôsobom je možné podstatne znížiť alergickú reakciu.When the nasal ointment corresponding to the present invention is applied only to the lower edge of the nostrils and around the nose, an inhalation allergic reaction cannot be prevented. However, if the ointment is applied correctly, the ointment may be at least partially avoided by inhalation allergens. Due to the specific physical properties, the nasal ointment corresponding to the present invention cannot penetrate the wall of the nasal mucosa, therefore it does not absorb and remains on the surface as a protective film. This creates a mechanical barrier to allergen carriers trapped and transported by inhaled air. In this way it is possible to substantially reduce the allergic reaction.
Ako sa opisuje už v patente DE-C 41 17 887, základnou výhodou predkladaného vynálezu je to, že zamedzuje výskytu alergických reakcií, bez toho, aby bol metabolizmus pacienta systematicky vystavovaný pôsobeniu účinných látok. Hlavnou zložkou nosovej masti sú už uvedené nasýtené uhľovodíky, ktoré sa správajú inertne a neabsorbujú sa nosovou sliznicou. To značí, že nosová masť zodpovedajúca predkladanému vynálezu sa môže používať celkom bez rizika. Navyše účinok masti neklesá ani pri dlhodobom používaní, čiže organizmus pacienta sa ani pri návykovom používaní nestáva proti masti rezistentný. Základné vzájomne súvisiace zmysly, čuch a chuť, sa používaním masti nenarušujú. Ďalšie výhody nosovej masti, ktoré je potrebné uviesť v súvislosti s predkladaným vynálezom, sú:As already described in DE-C 41 17 887, the basic advantage of the present invention is that it avoids the occurrence of allergic reactions without the patient's metabolism being systematically exposed to the active ingredients. The main constituents of the nasal ointment are the already mentioned saturated hydrocarbons, which behave inertly and do not absorb by the nasal mucosa. This means that the nasal ointment corresponding to the present invention can be used without risk. In addition, the effect of the ointment does not decrease even after prolonged use, so that the patient's organism does not become resistant to the ointment even under addictive use. Essential interrelated senses, smell and taste are not impaired by the use of ointment. Further advantages of the nasal ointment to be mentioned in connection with the present invention are:
- pomerne nízka cena;- relatively low price;
- pacient môže uskutočňovať vlastnú preventívnu liečbu;- the patient may carry out his own preventive treatment;
- aplikácia nosovej masti v súlade s predkladaným vynálezom s prísadou má súčasne efekt starostlivosti o sliznicu.application of a nasal ointment in accordance with the present invention with an additive also has a mucosal care effect.
Navyše, nosová masť podľa predkladaného vynálezu nielen zamedzuje alergickým reakciám - zdureniu nosovej sliznice, tečeniu z nosa a svrbeniu vnútri nosovej dutiny, ale tiež eliminuje dráždivé reakcie v oblasti očí a krku.In addition, the nasal ointment of the present invention not only prevents allergic reactions - swelling of the nasal mucosa, runny nose and itching inside the nasal cavity, but also eliminates irritating reactions in the eye and neck area.
V súlade s tým predkladaný vynález ráta s použitím aspoň jednej zmesi, ktorá je z farmaceutického a kozmetického hľadiska definovaná ako vazelína obsahujúca nasýtené uhľovodíky tak, ako je uvedené nárokoch 1 až 5, alebo ako nosová masť (prípadne masti) k ochrane oproti inhalačným alergickým reakciám. V tejto podobe je predovšetkým účinná pri alergickej nádche v podobe „sennej nádchy“.Accordingly, the present invention contemplates the use of at least one composition, defined from a pharmaceutical and cosmetic standpoint, as a petrolatum containing saturated hydrocarbons as set forth in claims 1 to 5 or as a nasal ointment (or ointment) to protect against inhalation allergic reactions . In this form it is particularly effective in allergic rhinitis in the form of "hay rhinitis".
Na záver je potrebné povedať, že pri vysokej efektivite nosovej masti a jej použitia v súlade s predkladaným vynálezom je možné očakávať dlhodobé spoľahlivý účinok pri použití veľmi malého množstva prípravku. Niekoľko miligramov masti rozotretých vnútri nosových dierok zaistí ochranu oproti nežiaducim symptómom na niekoľko hodín, bez toho, aby musela byť masť znova aplikovaná.In conclusion, with the high efficiency of the nasal ointment and its use in accordance with the present invention, a long-term reliable effect can be expected using a very small amount of formulation. A few milligrams of ointment spread inside the nostrils will provide protection against unwanted symptoms for several hours without having to re-apply the ointment.
Claims (6)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20009841U DE20009841U1 (en) | 2000-05-31 | 2000-05-31 | Vaseline-based nasal ointment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK12812000A3 SK12812000A3 (en) | 2001-12-03 |
| SK286019B6 true SK286019B6 (en) | 2008-01-07 |
Family
ID=7942316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1281-2000A SK286019B6 (en) | 2000-05-31 | 2000-08-24 | Nasal ointment for the prevention of inhalation allergic reactions |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20030161899A1 (en) |
| EP (2) | EP1159958A1 (en) |
| JP (2) | JP2001342131A (en) |
| KR (1) | KR20030030998A (en) |
| AT (1) | ATE493112T1 (en) |
| AU (1) | AU2001267504A1 (en) |
| BG (1) | BG64887B1 (en) |
| BR (1) | BR0003852A (en) |
| CA (1) | CA2413188A1 (en) |
| CZ (1) | CZ296192B6 (en) |
| DE (2) | DE20009841U1 (en) |
| EE (1) | EE04769B1 (en) |
| HR (1) | HRP20000559A2 (en) |
| HU (1) | HUP0003408A2 (en) |
| PL (1) | PL198950B1 (en) |
| RU (1) | RU2237468C2 (en) |
| SK (1) | SK286019B6 (en) |
| UA (1) | UA72734C2 (en) |
| WO (1) | WO2001091719A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20009841U1 (en) * | 2000-05-31 | 2001-10-25 | Phyt-Immun GmbH, 66424 Homburg | Vaseline-based nasal ointment |
| JP4614423B2 (en) * | 2004-04-30 | 2011-01-19 | フマキラー株式会社 | Nasal composition for allergic rhinitis |
| JP2006008516A (en) * | 2004-06-21 | 2006-01-12 | Nippon Kenko Kagaku Kenkyu Center:Kk | Nasal pollen allergy prevention ointment and nostril pollen allergy prevention ointment |
| JP2006312635A (en) * | 2005-04-08 | 2006-11-16 | Hinode Sangyo Kk | Nasal wall coating composition |
| NL2001342C2 (en) * | 2008-02-20 | 2009-08-24 | Cornelis Boegem | Balm for covering mucous membranes against allergenic substances present in the air, the use of the balm and an applicator for the balm. |
| JP5337984B2 (en) * | 2008-11-07 | 2013-11-06 | アース製薬株式会社 | Intranasal preparation and method for preventing sagging in nasal cavity |
| WO2013049539A1 (en) * | 2011-09-30 | 2013-04-04 | Mcneil-Ppc, Inc. | A method of blocking or trapping allergens |
| CN112076148B (en) * | 2019-06-12 | 2025-01-10 | 陕西佰傲再生医学有限公司 | Antiallergic gel for nasal use and preparation method thereof |
| AU2020230306A1 (en) * | 2020-09-10 | 2022-03-24 | Dao Cheng Song | It is a method to suppress/cure hay fever. Having some moisturiser (Lip Balm, Papaw Ointment) to wax around the inner nose it can effectively suppress hay fever. This invention is a guide for any manufacture interested in creating a product that consists of a similar type of ingredients and creating a specialised medical item, designed a sole purpose for coping hay fever. |
| JP7074388B1 (en) * | 2022-01-25 | 2022-05-24 | 株式会社オフィスシステムサービス | External nasal agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2095092A (en) * | 1936-02-21 | 1937-10-05 | Clorox Chemical Co | Ointment |
| DE3010572C2 (en) * | 1980-03-19 | 1982-05-06 | Süess, Hans R., Dr., Starrkirch | Skin care and skin protection preparations |
| DE3416209A1 (en) * | 1984-05-02 | 1985-11-21 | Mohamed Roshdy Dr Ismail | EYE TREATMENT PREPARATIONS |
| ES2053678T3 (en) * | 1987-11-13 | 1994-08-01 | Asta Medica Ag | PROCEDURE FOR PREPARING AN AZELASTIN CONTENT MEDICATION FOR NASAL AND / OR EYE APPLICATION. |
| DK0482208T3 (en) * | 1990-04-25 | 2000-09-18 | Nissan Chemical Ind Ltd | Pyridazinone derivatives |
| DE4117887C2 (en) * | 1990-06-09 | 1993-12-16 | Siegfried Rochler | Use of pharmaceutically / cosmetically defined petroleum jelly as a nasal ointment for the prophylaxis of inhalation allergic reactions |
| EP0529499A1 (en) * | 1991-08-22 | 1993-03-03 | Hoechst Aktiengesellschaft | Compositions for topical administration to the nose or the eyes containing bradykinin antagonists |
| RU2038071C1 (en) * | 1992-12-15 | 1995-06-27 | Дейгин Владислав Исакович | Face skin cream |
| DE4438589A1 (en) * | 1994-10-28 | 1995-03-23 | Reingard Dr Muenster | Nasal therapeutic agent |
| DE19544905A1 (en) * | 1995-12-01 | 1997-06-05 | Robugen Gmbh | Preparation of plant extracts |
| US5972327A (en) * | 1997-10-22 | 1999-10-26 | Lin; Matthew M. | Method of treating allergic rhinitis by delivering medication via the nasal vestibules |
| JPH11246416A (en) * | 1998-03-05 | 1999-09-14 | Nof Corp | Nasal drop additive and nasal drop |
| DE20002395U1 (en) * | 2000-02-13 | 2000-05-25 | Febena Pharma GmbH, 50825 Köln | Cream, especially for external use on the nasal skin |
| DE20009841U1 (en) * | 2000-05-31 | 2001-10-25 | Phyt-Immun GmbH, 66424 Homburg | Vaseline-based nasal ointment |
-
2000
- 2000-05-31 DE DE20009841U patent/DE20009841U1/en not_active Expired - Lifetime
- 2000-08-22 CZ CZ20003062A patent/CZ296192B6/en not_active IP Right Cessation
- 2000-08-24 SK SK1281-2000A patent/SK286019B6/en not_active IP Right Cessation
- 2000-08-24 EE EEP200000375A patent/EE04769B1/en not_active IP Right Cessation
- 2000-08-25 PL PL342179A patent/PL198950B1/en not_active IP Right Cessation
- 2000-08-25 RU RU2000122478/15A patent/RU2237468C2/en not_active IP Right Cessation
- 2000-08-25 HU HU0003408A patent/HUP0003408A2/en unknown
- 2000-08-27 UA UA2000085033A patent/UA72734C2/en unknown
- 2000-08-28 BR BR0003852-0A patent/BR0003852A/en not_active IP Right Cessation
- 2000-08-28 BG BG104714A patent/BG64887B1/en unknown
- 2000-08-28 JP JP2000257825A patent/JP2001342131A/en active Pending
- 2000-08-28 HR HR20000559A patent/HRP20000559A2/en not_active Application Discontinuation
- 2000-08-29 EP EP00118143A patent/EP1159958A1/en not_active Withdrawn
-
2001
- 2001-05-31 AU AU2001267504A patent/AU2001267504A1/en not_active Abandoned
- 2001-05-31 EP EP01945223A patent/EP1286657B1/en not_active Expired - Lifetime
- 2001-05-31 DE DE50115757T patent/DE50115757D1/en not_active Expired - Lifetime
- 2001-05-31 US US10/296,934 patent/US20030161899A1/en not_active Abandoned
- 2001-05-31 AT AT01945223T patent/ATE493112T1/en active
- 2001-05-31 WO PCT/EP2001/006197 patent/WO2001091719A1/en not_active Ceased
- 2001-05-31 KR KR1020027016096A patent/KR20030030998A/en not_active Ceased
- 2001-05-31 CA CA002413188A patent/CA2413188A1/en not_active Abandoned
-
2002
- 2002-02-14 US US10/077,259 patent/US20020082305A1/en not_active Abandoned
-
2006
- 2006-05-29 JP JP2006148823A patent/JP2006316063A/en active Pending
-
2012
- 2012-05-14 US US13/470,541 patent/US20120308671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030030998A (en) | 2003-04-18 |
| ATE493112T1 (en) | 2011-01-15 |
| WO2001091719A1 (en) | 2001-12-06 |
| EP1159958A1 (en) | 2001-12-05 |
| US20030161899A1 (en) | 2003-08-28 |
| US20120308671A1 (en) | 2012-12-06 |
| PL198950B1 (en) | 2008-08-29 |
| HUP0003408A2 (en) | 2002-09-28 |
| JP2006316063A (en) | 2006-11-24 |
| JP2001342131A (en) | 2001-12-11 |
| SK12812000A3 (en) | 2001-12-03 |
| AU2001267504A1 (en) | 2001-12-11 |
| UA72734C2 (en) | 2005-04-15 |
| CZ20003062A3 (en) | 2002-01-16 |
| BG104714A (en) | 2002-05-31 |
| DE20009841U1 (en) | 2001-10-25 |
| CZ296192B6 (en) | 2006-02-15 |
| EE04769B1 (en) | 2007-02-15 |
| DE50115757D1 (en) | 2011-02-10 |
| BG64887B1 (en) | 2006-08-31 |
| RU2237468C2 (en) | 2004-10-10 |
| BR0003852A (en) | 2002-07-23 |
| EE200000375A (en) | 2002-02-15 |
| PL342179A1 (en) | 2001-12-03 |
| CA2413188A1 (en) | 2001-12-06 |
| EP1286657A1 (en) | 2003-03-05 |
| HU0003408D0 (en) | 2000-08-25 |
| US20020082305A1 (en) | 2002-06-27 |
| EP1286657B1 (en) | 2010-12-29 |
| HRP20000559A2 (en) | 2001-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120308671A1 (en) | Nasal ointment based on white petroleum jelly | |
| WO2008045449A2 (en) | Composition for controlling the respiratory effects of inhaled pollutants and allergens | |
| NO20010830D0 (en) | Oral liquid mucoadhesive compositions | |
| US6929800B2 (en) | Nasal passage cleaning composition | |
| KR20060007007A (en) | Keratin composition with anti-allergic and anti-inflammatory properties | |
| WO2002069887A3 (en) | Virucidal compositions | |
| US9750706B2 (en) | Electrostatically charged nasal application method and product for micro-filtration | |
| JP2001240547A (en) | Hay fever inhibitor | |
| KR102212633B1 (en) | Cosmetic composition containing essential oil for preventing stress alopecia | |
| JPH101442A (en) | Rhinitis nasal drops | |
| Dodig et al. | Anti-IgE therapy with omalizumab in asthma and allergic rhinitis | |
| DK1107734T3 (en) | Oral liquid mucoadhesive compositions | |
| JP4614423B2 (en) | Nasal composition for allergic rhinitis | |
| CA2955664C (en) | Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis | |
| KR20120009667A (en) | Allergy disease prevention or treatment composition comprising egg white albumin as an active ingredient | |
| JP3127160U (en) | Anti-allergy, antibacterial, anti-influenza, anti-hay fever mask | |
| WO2006006283A1 (en) | Composition for nasal cavity | |
| JPS58203903A (en) | Agent for preventing citrus fruits from falling | |
| UA41123A (en) | Epithelization adhesive composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20100824 |